Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines

Spread of cancer to the brain remains an unmet clinical need in spite of the increasing number of cases among patients with lung, breast cancer, and melanoma most notably. Although research on brain metastasis was considered a minor aspect in the past due to its untreatable nature and invariable lethality, nowadays, limited but encouraging examples have questioned this statement, making it more attractive for basic and clinical researchers. Evidences of its own biological identity (i.e., specific microenvironment) and particular therapeutic requirements (i.e., presence of blood–brain barrier, blood–tumor barrier, molecular differences with the primary tumor) are thought to be critical aspects that must be functionally exploited using preclinical models. We present the coordinated effort of 19 laboratories to compile comprehensive information related to brain metastasis experimental models. Each laboratory has provided details on the cancer cell lines they have generated or characterized as being capable of forming metastatic colonies in the brain, as well as principle methodologies of brain metastasis research. The Brain Metastasis Cell Lines Panel (BrMPanel) represents the first of its class and includes information about the cell line, how tropism to the brain was established, and the behavior of each model in vivo. These and other aspects described are intended to assist investigators in choosing the most suitable cell line for research on brain metastasis. The main goal of this effort is to facilitate research on this unmet clinical need, to improve models through a collaborative environment, and to promote the exchange of information on these valuable resources.

[1]  D. Hanahan,et al.  Roadmap for the Emerging Field of Cancer Neuroscience , 2020, Cell.

[2]  F. Rödel,et al.  Evaluating Magnetic Resonance Spectroscopy as a Tool for Monitoring Therapeutic Response of Whole Brain Radiotherapy in a Mouse Model for Breast-to-Brain Metastasis , 2019, Front. Oncol..

[3]  A. Giobbie-Hurder,et al.  Targeting the PI3K/Akt/mTOR-pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. , 2019, Neuro-oncology.

[4]  F. Thorsen,et al.  Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases , 2019, Journal of Experimental & Clinical Cancer Research.

[5]  Costas D. Arvanitis,et al.  The blood–brain barrier and blood–tumour barrier in brain tumours and metastases , 2019, Nature Reviews Cancer.

[6]  Christopher M. Fife,et al.  Hematopoietic Stem Cell Gene Therapy for Brain Metastases Using Myeloid Cell–Specific Gene Promoters , 2019, Journal of the National Cancer Institute.

[7]  S. Knappskog,et al.  Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors , 2019, International journal of molecular sciences.

[8]  R. Bjerkvig,et al.  Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood–Brain Barrier , 2019, Molecular Cancer Therapeutics.

[9]  N. Erez,et al.  Inflammatory Activation of Astrocytes Facilitates Melanoma Brain Tropism via the CXCL10-CXCR3 Signaling Axis. , 2019, Cell reports.

[10]  M. Davies,et al.  AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis , 2019, Molecular Cancer Research.

[11]  P. Steeg,et al.  Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases , 2019, Oncogene.

[12]  Bin Liu,et al.  Dynamics of breast cancer relapse reveal late recurring ER-positive genomic subgroups , 2019, Nature.

[13]  N. Erez,et al.  A Blazing Landscape: Neuroinflammation Shapes Brain Metastasis. , 2019, Cancer research.

[14]  R. Jain,et al.  Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer , 2019, npj Breast Cancer.

[15]  Dawen Zhao,et al.  MRI evaluation of the effects of whole brain radiotherapy on breast cancer brain metastasis , 2019, International journal of radiation biology.

[16]  Jennifer S. Yu,et al.  Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma , 2018, Oncoimmunology.

[17]  N. Sibson,et al.  VCAM-1–targeted MRI Enables Detection of Brain Micrometastases from Different Primary Tumors , 2018, Clinical Cancer Research.

[18]  Costas D. Arvanitis,et al.  Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood–tumor barrier disruption , 2018, Proceedings of the National Academy of Sciences.

[19]  Joshua M. Dempster,et al.  Genetic and transcriptional evolution alters cancer cell line drug response , 2018, Nature.

[20]  I. Jurisica,et al.  Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis. , 2018, Cancer research.

[21]  M. Reiser,et al.  Micro-imaging of Brain Cancer Radiation Therapy Using Phase-contrast Computed Tomography. , 2018, International journal of radiation oncology, biology, physics.

[22]  M. Taketo,et al.  Genes to Cells , 2018 .

[23]  R. Soffietti,et al.  STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis , 2018, Nature Medicine.

[24]  J. Wilmott,et al.  Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. , 2018, The Lancet. Oncology.

[25]  E. Wong,et al.  Cranial irradiation increases tumor growth in experimental breast cancer brain metastasis , 2018, NMR in biomedicine.

[26]  A. Allan,et al.  Circulating Tumor Cell Analysis in Preclinical Mouse Models of Metastasis , 2018, Diagnostics.

[27]  P. Brastianos,et al.  The Evolving Landscape of Brain Metastasis. , 2018, Trends in cancer.

[28]  A. Melcher,et al.  Anti–PD-1/anti–CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking , 2018, Proceedings of the National Academy of Sciences.

[29]  F. Thorsen,et al.  Ultrasound-mediated delivery and distribution of polymeric nanoparticles in the normal brain parenchyma of a metastatic brain tumour model , 2018, PloS one.

[30]  N. Kasahara,et al.  A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models , 2017, Molecular therapy oncolytics.

[31]  Bart S. Hendriks,et al.  Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer , 2018, Pharmaceutical Research.

[32]  M. Valiente,et al.  Reactive Astrocytes in Brain Metastasis , 2017, Front. Oncol..

[33]  Yiling Lu,et al.  A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. , 2017, Cell reports.

[34]  Austin E. Gillen,et al.  Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases , 2017, Front. Oncol..

[35]  C. Miller,et al.  Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer , 2017, Neuro-oncology.

[36]  P. Canoll,et al.  Quality Assessment of Stereotactic Radiosurgery of a Melanoma Brain Metastases Model Using a Mouselike Phantom and the Small Animal Radiation Research Platform. , 2017, International journal of radiation oncology, biology, physics.

[37]  R. Salgia,et al.  State-of-the-art considerations in small cell lung cancer brain metastases , 2017, Oncotarget.

[38]  K. Ashkan,et al.  CD15s/CD62E Interaction Mediates the Adhesion of Non-Small Cell Lung Cancer Cells on Brain Endothelial Cells: Implications for Cerebral Metastasis , 2017, International journal of molecular sciences.

[39]  C. Miller,et al.  The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation , 2017, Science Translational Medicine.

[40]  Adrian V. Lee,et al.  Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases , 2017, JAMA oncology.

[41]  J. Massagué,et al.  Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis , 2017, Cell.

[42]  D. Greiner,et al.  Humanized Mouse Models of Clinical Disease. , 2017, Annual review of pathology.

[43]  J. Condeelis,et al.  Mechanism of early dissemination and metastasis in Her2+ mammary cancer , 2016, Nature.

[44]  C. Brennan,et al.  Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. , 2016, Cell reports.

[45]  J. Koblinski,et al.  NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice , 2016, PloS one.

[46]  W. Woodward,et al.  Computational Modeling of Micrometastatic Breast Cancer Radiation Dose Response. , 2016, International journal of radiation oncology, biology, physics.

[47]  P. Steeg,et al.  Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer , 2016, Pharmaceutical Research.

[48]  S. Soffer,et al.  Incipient Melanoma Brain Metastases Instigate Astrogliosis and Neuroinflammation. , 2016, Cancer research.

[49]  Wei Xu,et al.  miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. , 2016, Journal of the National Cancer Institute.

[50]  C. Anders,et al.  Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases. , 2016, Nanomedicine.

[51]  C. Bert,et al.  Novel technique for high-precision stereotactic irradiation of mouse brains , 2016, Strahlentherapie und Onkologie.

[52]  A. Vortmeyer,et al.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[53]  S. Steinberg,et al.  Alterations in Pericyte Subpopulations Are Associated with Elevated Blood–Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer , 2016, Clinical Cancer Research.

[54]  E. Winer,et al.  Combination inhibition of PI3K and mTORC1 yields durable remissions in orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases , 2016, Nature Medicine.

[55]  H. Wurdak,et al.  Metastatic site-specific polarization of macrophages in intracranial breast cancer metastases , 2016, Oncotarget.

[56]  J. Massagué,et al.  Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer , 2016, Nature.

[57]  Elisa de Stanchina,et al.  Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT , 2016, Cell.

[58]  R. Bosotti,et al.  Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications , 2016, Molecular Cancer Therapeutics.

[59]  L. Sequist,et al.  First‐Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[60]  R. Jain,et al.  Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. , 2016, Journal of the National Cancer Institute.

[61]  W. Wick,et al.  Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma , 2016, Molecular Cancer Therapeutics.

[62]  H. Heinzl,et al.  Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases , 2016, Oncoimmunology.

[63]  O. Garaschuk,et al.  Brain tumour cells interconnect to a functional and resistant network , 2015, Nature.

[64]  Jun Yao,et al.  Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth , 2015, Nature.

[65]  F. Winkler The brain metastatic niche , 2015, Journal of molecular medicine.

[66]  E. Guney,et al.  FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies , 2015, Oncotarget.

[67]  N. Socci,et al.  Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations. , 2015, Cancer research.

[68]  H. Cameron,et al.  Analysis of radiation therapy in a model of triple-negative breast cancer brain metastasis , 2015, Clinical & Experimental Metastasis.

[69]  V. Rohde,et al.  The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study , 2015, Oncotarget.

[70]  Lucio Crinò,et al.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  D. Hoon,et al.  Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells. , 2015, Cancer letters.

[72]  M. Esteller,et al.  Identification of HERC5 and its potential role in NSCLC progression , 2015, International journal of cancer.

[73]  Yusuke Yoshioka,et al.  Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood–brain barrier , 2015, Nature Communications.

[74]  Yueh Z. Lee,et al.  Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer , 2015, Molecular Cancer Therapeutics.

[75]  Weiying Zhou,et al.  Breast cancer-secreted miR-122 reprograms glucose metabolism in pre-metastatic niche to promote metastasis , 2015, Nature Cell Biology.

[76]  B. Wall,et al.  Riluzole is a radio‐sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells , 2015, Pigment cell & melanoma research.

[77]  Y. Mo,et al.  miR-509 suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF α , 2014, Oncogene.

[78]  H. Seol,et al.  Patient-Derived Xenografts from Non–Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy , 2014, Clinical Cancer Research.

[79]  Y. Kluger,et al.  PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis , 2014, Clinical Cancer Research.

[80]  Ruey-min Lee,et al.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. , 2014, The Lancet. Oncology.

[81]  W. Hahn,et al.  Analysis of tumor- and stroma-supplied proteolytic networks reveals a brain metastasis-promoting role for cathepsin S , 2014, Nature Cell Biology.

[82]  S. Steinberg,et al.  Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner , 2014, Clinical Cancer Research.

[83]  M. Kris,et al.  Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis , 2014, Cell.

[84]  S. Tavazoie,et al.  Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation , 2014, Cell.

[85]  R. Dummer,et al.  Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. , 2014, European journal of cancer.

[86]  B. Cornelissen,et al.  Selective Permeabilization of the Blood–Brain Barrier at Sites of Metastasis , 2013, Journal of the National Cancer Institute.

[87]  M. Hung,et al.  Inhibition of Type I Insulin-Like Growth Factor Receptor Signaling Attenuates the Development of Breast Cancer Brain Metastasis , 2013, PloS one.

[88]  W. Geldenhuys,et al.  Paclitaxel–Hyaluronic NanoConjugates Prolong Overall Survival in a Preclinical Brain Metastases of Breast Cancer Model , 2013, Molecular Cancer Therapeutics.

[89]  J. Golfinos,et al.  Development and characterization of a clinically relevant mouse model of melanoma brain metastasis , 2013, Pigment cell & melanoma research.

[90]  M. Westphal,et al.  Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. , 2013, The American journal of pathology.

[91]  R. Muschel,et al.  Ultrasonography-guided intracardiac injection: an improvement for quantitative brain colonization assays. , 2013, The American journal of pathology.

[92]  H. Li,et al.  Elevated PLGF contributes to small-cell lung cancer brain metastasis , 2013, Oncogene.

[93]  C. Perou,et al.  Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer , 2013, PloS one.

[94]  F. Dilmanian,et al.  Therapy model for advanced intracerebral B16 mouse melanoma using radiation therapy combined with immunotherapy , 2013, Cancer Immunology, Immunotherapy.

[95]  H. Immervoll,et al.  Automated tracking of nanoparticle-labeled melanoma cells improves the predictive power of a brain metastasis model. , 2013, Cancer research.

[96]  Y. Mo,et al.  miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. , 2013, Cancer research.

[97]  H. Immervoll,et al.  In vivo animal models for studying brain metastasis: value and limitations , 2013, Clinical & Experimental Metastasis.

[98]  R. Jain,et al.  Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases , 2012, Proceedings of the National Academy of Sciences.

[99]  P. Lollini,et al.  Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor , 2012, PloS one.

[100]  M. Brown,et al.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial , 2012, The Lancet.

[101]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[102]  H. Woo,et al.  Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis , 2011, Proceedings of the National Academy of Sciences.

[103]  P. Meltzer,et al.  Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain , 2011, Clinical & Experimental Metastasis.

[104]  H. Rugo,et al.  Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER , 2011, Clinical Cancer Research.

[105]  R. Jain,et al.  The biology of brain metastases—translation to new therapies , 2011, Nature Reviews Clinical Oncology.

[106]  K. Camphausen,et al.  Brain metastases as preventive and therapeutic targets , 2011, Nature Reviews Cancer.

[107]  I. Fidler The role of the organ microenvironment in brain metastasis. , 2011, Seminars in cancer biology.

[108]  H. Immervoll,et al.  A novel brain metastases model developed in immunodeficient rats closely mimics the growth of metastatic brain tumours in patients , 2011, Neuropathology and applied neurobiology.

[109]  P. Steeg,et al.  Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer , 2010, Clinical Cancer Research.

[110]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  B. Felding-Habermann,et al.  Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. , 2010, The American journal of pathology.

[112]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[113]  Jochen Herms,et al.  Real-time imaging reveals the single steps of brain metastasis formation , 2010, Nature Medicine.

[114]  Marc Ladanyi,et al.  WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis , 2009, Cell.

[115]  D. Schadendorf,et al.  Activation of p38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to Become Tolerogenic in Ret Transgenic Mice Spontaneously Developing Melanoma , 2009, Clinical Cancer Research.

[116]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[117]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[118]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[119]  J. Wilson,et al.  Identification of the murine firefly luciferase-specific CD8 T-cell epitopes , 2009, Gene Therapy.

[120]  S. Steinberg,et al.  Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. , 2008, Journal of the National Cancer Institute.

[121]  A. Vortmeyer,et al.  Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization , 2008, Clinical & Experimental Metastasis.

[122]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[123]  D. G. Hall,et al.  Characterization of brain and bone-metastasizing clones selected from an ethylnitrosourea-induced rat mammary carcinoma , 1994, Clinical & Experimental Metastasis.

[124]  Wei Liu,et al.  Transgenic mouse model for skin malignant melanoma , 1998, Oncogene.

[125]  S. Ostrand-Rosenberg,et al.  Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. , 1998, Cancer research.

[126]  R A Patchell,et al.  Brain metastases. , 1991, Neurologic clinics.

[127]  I. Fidler,et al.  Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals. , 1988, Cancer research.

[128]  R. Labet [Brain metastasis]. , 1957, Bulletin medical.